Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381911 | 1.00 | PDE4B (0.49) | PDE4BRORCTP53KDM4EMEN1 | |
| SCHEMBL24583221 | 0.89 | PDE4B (0.47) | PDE4BRORCKDM4EMEN1KMT2A | |
| SCHEMBL31455144 | 0.88 | PDE4B (0.47) | PDE4BRORCKDM4EMEN1KMT2A | |
| SCHEMBL30149798 | 0.87 | PDE4B (0.59) | PDE4BUSP30 | |
| SCHEMBL21381970 | 0.87 | PDE4B (0.59) | PDE4BUSP30 | |
| SCHEMBL17736163 | 0.84 | GPR119 (0.53) | PDE4BRORCTP53KDM4EKMT2A | |
| SCHEMBL31455485 | 0.83 | ALDH1A1 (0.44) | PDE4BRORCKDM4EMEN1KMT2A | |
| SCHEMBL23211833 | 0.83 | PDE4B (0.48) | PDE4BRORCKDM4ENAMPTUSP30 | |
| SCHEMBL19175230 | 0.83 | LMNA (0.44) | PDE4BRORCKDM4EMEN1KMT2A | |
| SCHEMBL30567982 | 0.83 | PDE4B (0.48) | PDE4BRORCKDM4ENAMPTUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | PDE4B 1379/4885RORC 2754/4885TP53 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.